Iron Sucrose Promotes Endothelial Injury and Dysfunction and Monocyte Adhesion/Infiltration

Vaijinath S. Kamanna, Shobha H. Ganji, Stanislav Shelkovnikov, Keith Norris, Nosratola D. Vaziri

Division of Nephrology and Hypertension, University of California, Irvine, Calif., VA Healthcare System, Long Beach, Calif., and Department of Internal Medicine, Charles Drew University, Los Angeles, Calif., USA

Abstract

Background/Aims: Intravenous (IV) iron preparations are widely used in the management of anemia in ESRD populations. Recent changes in reimbursement policy have dramatically increased the use of IV iron to lower the use of costly erythropoiesis-stimulating agents. These preparations are frequently administered without consideration of total body iron stores or presence of inflammation which is aggravated by excess iron. Endothelial injury and dysfunction are critical steps in atherosclerosis, thrombosis and cardiovascular disease. IV iron preparations raise plasma non-transferrin-bound iron which can promote oxidative stress, endothelial damage and dysfunction. We explored the effect of an IV iron preparation on endothelial cells, monocytes and isolated arteries.

Methods: Primary cultures of human aortic endothelial cells (HAEC) were treated with pharmacologically relevant concentrations of iron sucrose (10–100 µg/ml) for 4–24 h. Endothelial cell morphology, viability, and monocyte adhesion were tested. Endothelial function was assessed by measuring the vasorelaxation response to acetylcholine in normal rat thoracic aorta rings preincubated with iron sucrose (200 µg/ml).

Results: In contrast to the control HAEC which showed normal cobblestone appearance, cells treated with iron sucrose (50–100 µg/ml) for 4 h showed loss of normal morphological characteristics, cellular fragmentation, shrinkage, detachment, monolayer disruption, and nuclear condensation/fragmentation features signifying apoptosis. HAEC exposure to iron sucrose (10–100 µg/ml) increased monocyte adhesion 5- to 25-fold. Incubation in media containing 200 µg/ml iron sucrose for 3 h caused marked reduction in the acetylcholine-mediated relaxation in phenylephrine-precontracted rat aorta.

Conclusion: Pharmacologically relevant concentration of iron sucrose results in endothelial injury and dysfunction and marked increase in monocyte adhesion.

Introduction

Accelerated atherosclerosis and cardiovascular disease are the main cause of premature death in the ESRD population. Endothelial injury and dysfunction are critical steps in the pathogenesis of atherosclerosis, thrombo-
Iron Sucrose Promotes Endothelial Injury and Dysfunction

Iron sucrose (100 mg/ml) was purchased from American Regent, Inc. (Shirley, N.Y., USA).

**Cultured Endothelial Cells and Treatment**

Primary cultures of normal HAEC were grown to confluence in EBM-2 growth media (4–6 passages, in 6-well plates) and incubated in the absence (control) or presence of iron sucrose (10–100 μg/ml) for 4 or 24 h at 37°C. Morphological changes in HAEC were examined by phase contrast microscopy using Nikon Eclipse 300 inverted microscope (x20 magnification). Cell viability was tested by a cell growth determination kit using 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide (Sigma). Formation of MTT formazan crystals by viable cell mitochondrial dehydrogenases (an index of cell viability) was determined by measuring the optical density at 570 nm with an ELISA Reader (Molecular Devices).

In vitro studies with endothelial cells, we used iron sucrose at 10–100 μg/ml concentrations added in the culture media. The rationale for the choice of these concentrations was based on the anticipated plasma levels following administration of the approved doses of this drug (100 mg in hemodialysis patients and 300 mg IV in PD patients) considering the blood volume of about 5 l of which 60–70% in plasma where the drug is distributed. Given the large size of the iron complex, the distribution of the product is largely limited to plasma.

**Monocyte Adhesion to HAEC**

Human monocytic cell line (THP-1) was labeled with fluorescent dye by incubating with 2',7'-bis(2-carboxyethyl)-5,6-carboxy fluorescein acetoxymethyl ester (10 μg/ml) for 1 h. HAEC were preincubated with iron sucrose (10–100 μg/ml) for 4 h. Fluorescently labeled THP-1 cells were added to HAEC monolayers, and incubated for 1 h. Nonadherent THP-1 cells were removed by washing with PBS containing 1% FBS. Adhered monocytes were dissolved in 0.1% SDS, and the fluorescence intensity was measured with excitation and emission of 485/562 nm.

**Animals**

Fifteen male Sprague-Dawley rats (Harlan) weighing 250–300 g were purchased and housed in an AAALAC approved facility with a standard 12-hour day-night cycle (University of California, Irvine, Calif., USA). All procedures were approved by the University of California Irvine Institutional Animal Care and Use Committee. After anesthesia by ketamine, the animals were sacrificed by exsanguinations via cardiac puncture. Thoracic aorta was removed immediately.

**Thoracic Aorta Preparation**

Thoracic aorta between the aortic arch and diaphragm was dissected and placed in cold Krebs bicarbonate solution bubbled with 95% O₂ and 5% CO₂ and consisted of (in mM): NaCl, 118; KCl, 4.7; CaCl₂, 2.5; MgSO₄, 1.6; KH₂PO₄, 1.2; NaHCO₃, 24; D-glucose, 10. Tissues were cleaned to remove adipose adhering to the adventitia. The aortas were then sectioned into transverse rings of 3 mm in width.

**Tension Registration**

The aortic rings were carefully mounted between two triangles of 28-gauge stainless steel. The rings were then vertically placed in an organ bath containing 10 ml of Krebs solution, heat-

**Methods**

**Cells, Drugs, and Chemicals**

Primary cultures of normal human aortic endothelial cells (HAEC) and HAEC growth media were obtained from Lonza (Walkersville, Md., USA). Human monocytic/macrophage THP-1 cell line was purchased from American Type Culture Collection (Rockville, Md., USA). Acetylcholine iodide, phenylephrine, and D-glucose were purchased from Sigma Chemical Co. (St. Louis, Mo., USA). Iron sucrose (100 mg/ml) was purchased from American Regent, Inc. (Shirley, N.Y., USA).
Effect of iron sucrose on cellular morphology: HAEC were grown in 6-well plates in EBM-2 growth media for 2 days to attain about 80% confluency. Cells were treated with various concentrations of iron sucrose (10–100 μg/ml) for 4 h. Morphological changes in HAEC were examined by phase contrast microscopy using Nikon Eclipse 300 inverted microscope (×20 magnification). a Control, b 10 μg/ml iron sucrose, c 50 μg/ml iron sucrose, d 100 μg/ml iron sucrose.

**Concentration-Response Curves**

All concentration-response curves were obtained by the cumulative addition of select compounds, allowing the force to reach steady-state before the addition of the next concentration. Drugs were added to the organ bath in volumes from 1 to 100 μl. Contractile effect of potassium was measured in the beginning of each experiment. In experiments with KCl (6–80 mM), the NaCl concentration was reduced accordingly in order to maintain constant osmolarity. Then, tissues were washed twice with fresh Krebs solution, allowed to equilibrate back to baseline for 90 min, and then PhE concentration-response curves were obtained. Subsequently, the tissues were washed six times with fresh Krebs, and again allowed to re-equilibrate for 90 min. Relaxation response to acetylcholine was determined after precontraction with 1 μM phenylephrine, which evokes maximal contraction. Phenylephrine contraction alone was found to be stable for at least the 40 min in which the studies were completed. Iron sucrose was added at a concentration of 200 μg/ml to the bath containing the aorta rings 4 h before the study. Maximal effect and the concentrations causing 50% of maximal response were used as the measure of sensitivity.

**Statistical Analysis**

All values are reported as means and standard error of the mean (SEM); they were calculated using the PRIZM v4 program (GraphPad Software, San Diego, Calif., USA). Statistical comparisons between data groups were performed using paired Student’s t test. For all statistical tests, p < 0.05 level of confidence was accepted for statistical significance.

**Results**

**Effect of Iron Sucrose on Cultured Endothelial Cells**

As shown by phase-contrast microscopy, control HAEC showed normal morphology with typical cobblestone appearance (fig. 1a). However, cells treated with iron sucrose (50 and 100 μg/ml) for 4 h lost normal morphological characteristics and showed the presence of cellular fragmentation and debris (fig. 1c, d). Many of the cells shrunk and detached from the plates, and the monolayer was disrupted in cells treated with iron sucrose at 50 and 100 μg/ml (fig. 1c, d). Additionally, many cells treated with iron sucrose at 50 and 100 μg/ml exhibited typical features of apoptosis including condensed and/or fragmented nuclei when compared to control cells (fig. 1c and d vs. a). Although cells treated with lower concentrations of iron sucrose (10 μg/ml) showed relatively normal gross morphology at 4 h, there were subtle and early signs of alterations in cellular morphology including cellular swelling (fig. 1b). Moreover, treatment with iron sucrose as low as 10 μg/ml for 24 h resulted in considerable morphological changes and appearance of early cellular fragments and debris in cultured endothelial cells. Treatment at 50–100 μg/ml for 24 h showed much higher alterations in cellular morphology as compared to 4-hour treatment (data not shown). Additional studies were performed to directly determine the effect of iron sucrose on cellular viability and/or cytotoxicity by assessing mitochondrial dehydrogenase activity using MTT assay kit. Increased formation of...
Iron Sucrose Promotes Endothelial Injury and Dysfunction

MTT formazan purple crystals by viable cell mitochondrial dehydrogenase represents increased number of viable cells. As shown in figure 2, iron sucrose (10–100 μg/ml) dose-dependently decreased cellular viability. Iron sucrose at 50 and 100 μg/ml concentrations caused severe cellular toxicity as only about 20% cells were viable.

**Effect of Iron Sucrose on Monocyte-Endothelial Interaction**

We further examined the impact of iron sucrose-mediated endothelial cell injury on monocyte adhesion, one of the key early pathobiological events involved in endothelial dysfunction and atherosclerosis. Treatment of HAEC with iron sucrose at concentration as low as 10 μg/ml for 4 h, markedly increased monocyte adhesion 5-fold (fig. 3). At 50 and 100 μg/ml, iron sucrose robustly induced monocyte adhesion 25-fold as compared to controls (fig. 3).

**Effect of Iron Sucrose on Endothelial Function**

Cumulative concentration-response curve in the phenylephrine (1 μM)-precontracted endothelium-intact rat thoracic aorta rings showed a marked reduction in acetylcholine-mediated relaxation by iron sucrose (fig. 4a). In fact, preincubation in media containing iron sucrose lowered the maximum relaxation response to acetylcholine by greater than 50% (fig. 4b). These findings point to the induction of endothelial dysfunction by iron sucrose. The observed endothelial dysfunction in iron sucrose-exposed artery rings represents the functional counterpart of the injury seen in the cultured endothelial cells.

**Discussion**

The present study revealed that iron sucrose, a commonly used IV iron preparation, causes a significant dose- and time-dependent injury in cultured human endothelial cells and promotes endothelial dysfunction as evidenced by marked reduction in acetylcholine-induced relaxation in the arterial tissue. In addition, exposure to the IV iron preparation resulted in a marked increase in monocyte adhesion to the cultured endothelial monolayer simulating arterial wall in vitro, events that are central to the pathogenesis of atherosclerosis. Although these in vitro studies provide evidence for the deleterious effects of iron sucrose on endothelial cell structure and function, caution should be exercised in extrapolation of the findings to the clinical setting.

Mechanistically, by catalyzing the Fenton reaction, iron converts hydrogen peroxide, a relatively innocuous...
and easily containable reactive oxygen species (ROS), to hydroxyl radical (•OH) which is the most reactive and cytotoxic ROS known (H₂O₂ + Fe²⁺ → •OH + OH⁻ + Fe³⁺). The participation of iron in oxidative reaction is perpetuated by subsequent conversion of iron from the ferric to the ferrous state in the presence of endogenous superoxide (O₂⁻) via the Haber-Weiss reaction (Fe³⁺ + O₂⁻ → Fe²⁺ + O₂), or by reducing agents such as vitamin C. Iron-induced oxidative stress plays an important part in the pathogenesis of endothelial injury and dysfunction. Administration of IV iron preparations, particularly when used indiscriminately, increases the plasma level of catalytically active, non-transferrin bound labile iron which is capable of causing oxidative stress [12]. In fact, several studies have documented the ability of IV iron preparations to cause oxidative stress in dialysis patients and in experimental animals [13–17]. Oxidative stress, in turn, results in endothelial damage and dysfunction and triggers inflammation via activation of NF-κB, a redox-sensitive transcription factor, which is a master regulator of numerous proinflammatory cytokines and chemokines. The constellation of endothelial damage and dysfunction, heightened monocyte adhesion in response to the IV iron preparation used in this study is consistent with the iron-induced oxidative stress. These conclusions are supported by several clinical and experimental studies. For instance, IV iron preparations (particularly iron sucrose) have been shown to inhibit proliferation and promote apoptosis in cultured endothelial cells [18]. Infusion of iron sucrose in healthy subjects has been reported to raise plasma non-transferrin-bound iron, significantly increase ROS production and acutely impair endothelium-dependent flow-mediated vasodilation induced by brachial artery occlusion [19]. Moreover, IV iron infusion in hemodialysis patients has been shown to significantly increase plasma lipid peroxidation products and induce monocyte IL-8 expression, events which could be partially attenuated by addition of N-acetylcysteine [20]. Finally, cross-sectional studies have shown an association between carotid artery media thickness and the cumulative dose of IV iron and plasma ferritin level in hemodialysis patients [21].

As noted above, via activation of NF-κB, oxidative stress can trigger inflammation. Therefore, IV iron preparations, particularly when used without extreme caution, can promote inflammation. In fact, injection of iron sucrose or iron gluconate in mice has been shown to significantly increase plasma and tissue (liver, renal, and lung) MCP-1, a major proinflammatory mediator, for at least 24 h [22]. Likewise, infusion of iron sucrose has been shown to result in a transient but significant increase in plasma MCP-1 level in patients with CKD. Repeat IV iron infusion one week later resulted in a lower peak but a more persistent elevation of plasma MCP-1 level [13].
nally, intravenously administered iron has been shown to be taken up by circulating monocytes leading to increase in their iron content and acute activation of the NF-κB pathway [23]. Elevation of hepcidin with iron overload contributes to accumulation of iron in the monocytes and macrophages. Accumulation of excess iron results in their transformation to the highly proinflammatory M1 macrophage population as shown in humans and experimental animals [24]. Together, these observations provide compelling evidence for the critical role of iron in the pathogenesis of atherosclerosis and cardiovascular disease [25].

In conclusion, the results of the present investigation build upon previous studies, and provide compelling evidence for the potential adverse cardiovascular effects of the indiscriminate use of the IV iron preparations in the highly vulnerable patients with advanced CKD.

Acknowledgements

This project was in part funded by the NIH grants R026138 and MD000182 (PI, Dr. Keith Norris). The authors wish to thank Mr. Neil Hoa (VA Long Beach) for assisting in phase contrast microscopy.

Disclosure Statement

Authors do not have any conflict of interest.

References